TY - JOUR
T1 - Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel
AU - Glatman-Freedman, Aharona
AU - Hershkovitz, Yael
AU - Dichtiar, Rita
AU - Rosenberg, Alina
AU - Keinan-Boker, Lital
AU - Bromberg, Michal
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023/4
Y1 - 2023/4
N2 - We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.
AB - We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.
UR - http://www.scopus.com/inward/record.url?scp=85150606239&partnerID=8YFLogxK
U2 - 10.3201/eid2904.221285
DO - 10.3201/eid2904.221285
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36863005
AN - SCOPUS:85150606239
SN - 1080-6040
VL - 29
SP - 771
EP - 777
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 4
ER -
